



#9
10/23/01 1644
PATENT

Attorney Docket No. 350013-66

CERTIFICATE OF MAILING

hereby certify that on October 5, 2001 this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

37 CFR 1.8(a)
 with sufficient postage
Office
as first class mail
Mailing Label

37 CFR 1.10
 as "Express Mail Post
to Addressee"
No. _____

HALEH SHARIFI

(Type or print name of person mailing paper)

H. Sharifi.
(Signature of person mailing paper)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Assistant Commissioner of Patents
Washington, D.C. 20231

RESPONSE TO OFFICE ACTION

In response to the office action dated September 07, 2001 requiring an election, Applicant elects, with traverse, the following embodiments, as originally described by the Examiner in Section 3 of the April 20, 2001 Office Action.

Applicant respectfully elects:

3.1) As to a specific embodiment of the method of identifying an antigen-responsive T cell, species **A**) the steps of determining for each of a plurality of T cell receptors, as recited in claim 1 is elected.

3.2) As to a specific embodiment of the method of identifying an antigen-responsive T cell, species **B**) steps wherein a sample is obtained from a non-diseased individual and from a diseased individual, as recited in claim 5 is elected.

RECEIVED
OCT 12 2001
TECH CENTER 1600 (200)
With a transmittal
10/23/01

3.3) As to a specific embodiment of the method of identifying an antigen-responsive T cell wherein the subset of T cell receptors is a subset, species A) each T cell receptor comprises a specific alpha region, as recited in claim 6 is elected.

3.4) As previously selected , i.e. species A) the specific embodiment of the method of identifying an antigen-responsive T cell wherein the method comprises a method which quantitates the amount of specific T cell receptor RNA or the amount of T cell receptor RNA in a specific subset, as recited in claims 2-11, is elected.

3.5) As to a specific embodiment of the method of treating a patient with an antigen mediated disease, species A) T cell vaccination, as recited in claim 20 is elected.

In light of the above elections, Claims 1-11, 18-20 are readable on the elected embodiments. A favorable action is requested on generic claims 1 and 18-20, and elected species claims 2-11.

The Commissioner is hereby authorized to charge any additional filing fees under 37 C.F.R. § 1.16, or application processing fees under 37 C.F.R. § 1.17, which may be required now or during the pendency of this application, or credit any overpayment to Account No. 16-2230. A duplicate copy of this sheet is enclosed.

Applicant thanks the Examiner for the latest communication and notes that this response is being mailed within the one month time period specified in the Office Communication of September 7, 2001.

Dated: October 4, 2001



Guy Porter Smith, Reg. No. 20,148
OPPENHEIMER WOLFF & DONNELLY LLP
2029 Century Park East, Suite 3800
Los Angeles, California 90067
(310) 788-5000